RELIEF-THERAPEUTICS
PX’Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and RELIEF THERAPEUTICS Holding AG (“Relief”, SIX : RLF), a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain diabetes-related complications, respiratory disorders and rare diseases, have announced today a strategic collaboration agreement for the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin-6.
This Medicinal Product Candidate (MPC) aims to fulfill an unmet medical need in peripheral diabetic neuropathy by regenerating damaged nerve fibers, stimulating remyelination and reducing neuropathic symptoms. No existing marketed therapies for peripheral neuropathy are able to regenerate damaged peripheral nerves. As such, therefore, atexakin alfa could become the first truly disease-modifying drug for this condition.
In this project, PX’Therapeutics will develop an optimized production process for recombinant interleukin 6, a 185-amino acids cytokine, in CHO cells. PX’Therapeutics will also produce, in accordance with current Good Manufacturing Practices (cGMP) guidelines, protein batches that will be used for clinical trials.
Gaël Hédou, COO of Relief, comments: "This collaboration is a key step in the advancement of the atexakin alfa project, and we are delighted to be able to rely on the expertise of PX’Therapeutics to complete the production necessary to implement our clinical trials".
Claire Untereiner, COO of PX’Therapeutics adds: "We are looking forward to this new collaboration with the Relief team for the development of this promising molecule. Based on the low doses required, we hope to be able to support Relief very far in its development, maybe even all the way to market…"
About RELIEF THERAPEUTICS Holding AG:
RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with a division of the global established pharmaceutical firm Merck KGaA, and has been the subject of multiple clinical trials and representing a major capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.
. For more information, please visit: www.relieftherapeutics.com
About PX’Therapeutics:
Located in Grenoble, PX’Therapeutics (a subsidiary of the pharmaceutical group Aguettant) is a biotechnology company specializing in engineering, process development and bioproduction of recombinant proteins, including monoclonal antibodies. Since its incorporation in 2000, PX’Therapeutics has played a very active role in the optimization, development and production of target proteins or therapeutic candidates for public and private laboratories and biotechnology companies based in Europe and North America. For more information, please visit: www.px-therapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161005005858/en/
Contact:
PX’Therapeutics:
Claire Untereiner
C.O.O.
Claire.untereiner@px-therapeutics.com
or
RELIEF
THERAPEUTICS Holding AG
Dr. Raghuram Selvaraju
Investor
Relations
Tel: +41 44 723 59 59
investors@relieftherapeutics.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante Launches World's First Commercial Gigafactory for Carbon Capture & Removal Filters13.5.2025 22:50:00 CEST | Press release
This next-generation carbon capture and removal solution represents a generational leap forward for managing carbon emissions from industrial sectors such as pulp & paper, waste-to-energy, cement, steel, and energy. Svante Technologies Inc. (Svante), a global leader in carbon capture and removal technologies, has officially completed the commissioning of its new Centre of Excellence for Carbon Capture and Removal – Redwood manufacturing Facility (Redwood) in Burnaby, British Columbia. This milestone marks the launch of the world's first gigafactory dedicated to producing commercial-scale carbon capture and removal filters designed to trap CO2 directly from industrial emissions and the atmosphere, and with the mindset of high-volume automation and product standardization to lower the manufacturing cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513713072/en/ Claude Letourneau, President & CEO, Svante Group opens the S
Svante and SAMSUNG E&A Sign Joint Development Agreement to Offer Digitally Enabled Skid-Mounted Modular Carbon Capture Plants13.5.2025 22:46:00 CEST | Press release
Svante and SAMSUNG E&A have signed a joint development agreement to offer standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm™ solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. Standardized modular packages will be branded and marketed globally by Svante and SAMSUNG E&A to deliver commercial carbon capture, use, and storage projects from the early project development stage through to engineering, procurement, and fabrication (EPF) across the heavy industrial and energy sectors. Svante Technologies Inc. (Svante) and SAMSUNG E&A announced today that they have signed a joint development agreement to jointly develop a set of standardized skid-mounted modular carbon capture plants based on Svante’s novel VeloxoTherm solid sorbent-based carbon capture filter technology, leveraging SAMSUNG E&A’s advanced digital solutions and modularization capabilities. The agreeme
AWS and HUMAIN Announce Groundbreaking AI Zone to Accelerate AI Adoption in Saudi Arabia and Globally13.5.2025 18:09:00 CEST | Press release
More than $5 billion joint investment in AI infrastructure, AWS services, and AI training and talent development will advance Saudi Arabia’s mission to be a global leader in AI Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, Saudi Arabia’s newly created company responsible for driving AI innovation across the Kingdom and globally, today announced plans to invest $5 billion-plus in a strategic partnership to build a groundbreaking “AI Zone” in the Kingdom. This first-of-a-kind AI Zone will bring together multiple innovative capabilities, including dedicated AWS AI infrastructure and servers with world-class semiconductors, UltraCluster networks for faster AI training and inference, AWS services like SageMaker and Bedrock, and AI application services such as Amazon Q to advance Saudi Arabia’s mission to be a world leader in AI. AWS previously announced and is currently building an AWS infrastructure region in Saudi Arabia that will become availabl
Citco enters strategic partnership with GIC13.5.2025 17:05:00 CEST | Press release
The Citco group of companies (Citco) and GIC are pleased to announce that they have entered a long term, strategic relationship. As part of the relationship, GIC, a global institutional investor, has become a minority shareholder in Citco. The founding Smeets Family shall remain the majority shareholder in Citco. “Citco has organically grown into a global market-leading asset servicing business, delivering value to investors like GIC for over 50 years. Our investment aligns squarely with GIC’s commitment to building long-lasting partnerships that empower family-owned businesses to thrive. With a combination of client-centric solutions and savvy technological investments Citco is at the forefront of their industry. We look forward to partnering with Citco and the Smeets family as we embark on this new chapter together." – Girish Karira, Head of Integrated Strategies Group and Head, New York Office at GIC. “We look forward to continuing our strategic relationship with GIC. Their industry
Tigo Energy Resolves Multi-Year Patent Infringement Litigation With SMA13.5.2025 15:00:00 CEST | Press release
Settlement validates Tigo Intellectual Property, concludes IP litigation with SMA, and reinforces innovation in the marketplace. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that it has reached a multi-year settlement with SMA (SMA Solar Technology AG and SMA Solar Technology America LLC) over litigation regarding the infringement of Tigo intellectual property by SMA. The settlement concludes the infringement complaint brought by Tigo on July 11, 2022, Case No. 1:22-cv-00915 (D. Del.) alleging infringement of certain patents by SMA. Terms of the settlement will remain undisclosed. According to National Electric Code § 690.12, “Rapid Shutdown of PV Systems on Buildings” requires that PV system circuits “installed on or in buildings shall include a rapid shutdown function to reduce shock hazard for emergency responders.” Tigo rapid shutdown technology is compliant with UL 1741, the Standard
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom